IRONWOOD PHARMACEUTICALS INC
Small-molecule therapeutics for gastrointestinal diseases
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Latest Form D
- $150M, Oct 2016
- Total capital
- $365M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $365M
- 5 Form D · last Oct 2016
- 121 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 34 pending · first 2017
- Rank in peer group#105 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$150M
- Private capital raisedForm D · SEC · 4th filing$175M
- Private capital raisedForm D · SEC · 3rd filing$15M
- Private capital raisedForm D · SEC · 2nd filing$25M
- Private capital raisedForm D · SEC · 1st filing$250K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#105 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- ANDREW E. DREYFUSDirectorNamed in SEC Form D filings
- BRYAN E. ROBERTSDirectorNamed in SEC Form D filings
- CHRISTOPHER T. WALSHDirectorNamed in SEC Form D filings
- DAVID EBERSMANDirectorNamed in SEC Form D filings
- DAVID T. SHAWDirectorNamed in SEC Form D filings
- DOUGLAS E. WILLIAMSDirectorNamed in SEC Form D filings
Show all 21 people
- EDWARD P. OWENSDirectorNamed in SEC Form D filings
- GEORGE H. CONRADESDirectorNamed in SEC Form D filings
- GINA BORNINO MILLERDirectorNamed in SEC Form D filings
- HALLEY E. GIBLERTExecutive OfficerNamed in SEC Form D filings
- JOSEPH C. COOK, JR.DirectorNamed in SEC Form D filings
- JULIE H. MCHUGHDirectorNamed in SEC Form D filings
- LAWRENCE S. OLANOFFDirectorNamed in SEC Form D filings
- MARK G. CURRIEExecutive OfficerNamed in SEC Form D filings
- MARSHA G. FANUCCIDirectorNamed in SEC Form D filings
- MICHAEL J. HIGGINSExecutive OfficerNamed in SEC Form D filings
- PETER M. HECHTExecutive Officer, DirectorNamed in SEC Form D filings
- STEPHEN KNIGHTDirectorNamed in SEC Form D filings
- TERRANCE G. MCGUIREDirectorNamed in SEC Form D filings
- THOMAS M. GRANEYExecutive OfficerNamed in SEC Form D filings
- THOMAS G. MCCOURTExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 6 granted of 40- PendingSynthetic Process for Production of Modified GCC Receptor AgonistsUSPTOApplication 18710964
- PendingPharmaceutical Compositions For The Treatment Of Visceral PainUSPTOApplication 18711317
- PendingSynthetic Process for Production of Modified GCC Receptor AgonistsUSPTOApplication 18711044
Show all 40 patent records
- Synthetic Process for Production of Modified GCC Receptor AgonistsOct 23, 2025 · Application 18710964Pending
- Pharmaceutical Compositions For The Treatment Of Visceral PainOct 16, 2025 · Application 18711317Pending
- Synthetic Process for Production of Modified GCC Receptor AgonistsJun 19, 2025 · Application 18711044Pending
- Compositions for Colon Cleansing and the Treatment of Gastrointestinal DisordersJun 20, 2024 · Application 18424114Pending
- Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel SyndromeNov 2, 2023 · Application 18351740Pending
- Treatments for Gastrointestinal DisordersOct 26, 2023 · Application 18336104Pending
- Treatments For Gastrointestinal DisordersAug 31, 2023 · Application 18143892Pending
- Methods Of Treating Upper Gastrointestinal Disorders In Ppi Refractory GerdAug 10, 2023 · Application 18300939Pending
- Efficacy of a Gastro-Retentive Bile Acid Sequestrant Dosage FormJun 22, 2023 · Application 16631208Pending
- Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel SyndromeJun 8, 2023 · Application 18058869Pending
- Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantNov 24, 2022 · Application 17881714Pending
- Treatments for Gastrointestinal DisordersJul 21, 2022 · Application 17716560Pending
- Modified or Targeted Release Formulations of LinaclotideJun 30, 2022 · Application 17692280Pending
- Methods Of Treating Upper Gastrointestinal Disorders In Ppi Refractory GerdMay 5, 2022 · Application 17575265Pending
- Treatments for Gastrointestinal DisordersApr 21, 2022 · Application 17566241Pending
- Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantApr 14, 2022 · Application 17556210Pending
- Treatments for Gastrointestinal DisordersDec 16, 2021 · Application 17459451Pending
- Methods Of Treating Upper Gastrointestinal Disorders In Ppi Refractory GerdSep 23, 2021 · Application 17336518Pending
- Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid SequestrantSep 2, 2021 · Application 17314213Pending
- Treatments for Gastrointestinal DisordersFeb 4, 2021 · Application 17066802Pending
- Gastro-retentive Sustained-release Oral Dosage Form Of A Bile Acid SequestrantJan 21, 2021 · Application 17039662Pending
- Treatments for Gastrointestinal DisordersSep 10, 2020 · Application 16881198Pending
- Method of Generating Anti-Linaclotide Antibodies and Uses ThereofMay 14, 2020 · Application 16407457Pending
- Method of Detecting and Quantifying Bile Acid from SalivaMay 7, 2020 · Application 16631214Pending
- Methods Of Treating Upper Gastrointestinal Disorders In Ppi Refractory GerdApr 16, 2020 · Application 16424310Pending
- Compositions for Colon Cleansing and the Treatment of Gastrointestinal DisordersApr 14, 2020 · US 10,618,938Granted
- Modified or Targeted Release Formulations of LinaclotideNov 21, 2019 · Application 16525784Pending
- Sgc StimulatorsNov 14, 2019 · Application 16209313Pending
- Salts, Co-crystals, And Polymorphs Of An Anxiolytic CompoundApr 23, 2019 · US 10,266,529Granted
- Treatments for Gastrointestinal DisordersFeb 28, 2019 · Application 16171524Pending
- Pyrazole Derivatives As Sgc StimulatorsJan 31, 2019 · Application 15902708Pending
- sGC STIMULATORSJan 22, 2019 · US 10,183,021Granted
- Compositions Comprising File Acid Sequestrants For Treating Esophageal DisordersAug 23, 2018 · Application 15813850Pending
- sGC STIMULATORSAug 14, 2018 · US 10,047,095Granted
- Treatments for Gastrointestinal DisordersJul 5, 2018 · Application 15906744Pending
- Imidazotriazinone CompoundsMay 15, 2018 · US 9,969,742Granted
- Methods Of Treating Upper Gastrointestinal Disorders In Ppi Refractory GerdJan 18, 2018 · Application 15548467Pending
- Methods and Compositions for the Treatment of Gastrointestinal DisordersDec 12, 2017 · US 9,840,536Granted
- sGC STIMULATORSOct 19, 2017 · Application 15511891Pending
- Pyrazole Derivatives As Sgc StimulatorsOct 12, 2017 · Application 15511900Pending
Related companies, and why
- Carogen CorporationSimilar federal contract value in Biotech · null in contracts
- ALKEUS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- IMMUNIC, INC.Similar federal contract value in Biotech · null in contracts
- Lycia TherapeuticsSimilar federal contract value in Biotech · null in contracts
- BioNTech SESimilar federal contract value in Biotech · null in contracts
- Attralus, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .